ATHE ALTERITY THERAPEUTICS LIMITED
Price Chart
Executive Summary
Alterity Therapeutics announced a peer-reviewed publication in NeuroImage demonstrating that QSM MRI can detect disease-specific iron accumulation in MSA patients, distinguish MSA from Parkinson's disease, and correlate with clinical severity. The company remains on track for an End-of-Phase 2 meeting with the FDA in mid-2026 to initiate a Phase 3 trial of ATH434.
Actionable Insight
The peer-reviewed validation of QSM MRI as a biomarker de-risks the Phase 3 program for ATH434 in MSA. Monitor for the End-of-Phase 2 meeting outcome in mid-2026, which could trigger a catalyst for the stock. The strong historical win rate (100% at T+20) suggests positive momentum may continue.
Key Facts
- Peer-reviewed study in NeuroImage validates QSM MRI as a biomarker for iron dysregulation in MSA.
- QSM MRI distinguished MSA from Parkinson's disease with moderate-to-good accuracy (AUC = 0.76–0.79).
- Higher iron content correlated with greater disease severity on UMSARS.
- Alterity is on track for End-of-Phase 2 meeting with FDA in mid-2026.
- ATH434 has Fast Track and Orphan Drug Designations from FDA and European Commission.
- Phase 2 trial showed robust clinical efficacy, target engagement, and favorable safety profile.
Financial Impact
No financial figures disclosed; publication supports biomarker validation for ATH434 Phase 3 program.
Risk Factors
- Phase 3 trial may fail to replicate Phase 2 efficacy results.
- Regulatory feedback from End-of-Phase 2 meeting could delay or require additional studies.
- Small market cap ($72M) and OTC listing increase volatility and liquidity risk.
- No revenue or near-term commercialization timeline.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291770 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
6-K
| $4.15 awaiting T+5 | awaiting T+5 | — | $4.21 (+1.57%) |
|
Jun 9, 2026
5d ago
|
Press Release
| $3.92 awaiting T+5 | awaiting T+5 | — | $4.21 (+7.40%) |
|
May 11, 2026
4w ago
|
Press Release
| $4.80 $4.34 | ▼ −9.58% | ▼ −9.50% | $4.21 (−12.29%) |
|
Apr 30, 2026
6w ago
|
Press Release
| $4.54 $4.67 | ▲ +2.86% | ▲ +1.14% | $4.21 (−7.27%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.62 $4.52 | ▼ −2.16% | ▼ −2.56% | $4.21 (−8.87%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $4.54 $4.57 | ▲ +0.66% | ▲ +0.61% | $4.21 (−7.27%) |
|
Mar 26, 2026
11w ago
|
6-K
| $3.16 $3.56 | ▲ +12.66% | ▲ +11.02% | $4.21 (+33.23%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $3.45 $3.55 | ▲ +2.90% | ▲ +4.11% | $4.21 (+22.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access